ArticleTranslational vision science & technology2026
Retinal Ischemic Perivascular Lesions Screen for Vision-Threatening Diabetic Retinopathy Visualized on Ultra-Widefield Fluorescein Angiography.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To validate retinal ischemic perivascular lesions (RIPLs) as an optical coherence tomography (OCT) biomarker for vision-threatening diabetic retinopathy (VTDR), using ultra-widefield fluorescein angiography (UWF-FA) as the grading reference. Methods: This retrospective cohort study included 76 patients (97 eyes) with diabetic retinopathy (DR), who underwent same-day UWF-FA and OCT at Northwestern Memorial Hospital. DR severity was graded on UWF-FA. RIPLs were identified on a per-lesion basis using 61 serial B-scans from Heidelberg SPECTRALIS OCT (30° × 25° field of view). RIPLs were defined as thinning of the inner nuclear layer, disruption of the outer plexiform layer, and elevation of the outer nuclear layer. Two independent graders assessed the RIPL counts, and the intraclass correlation coefficient (ICC) was calculated. Associations between RIPL count and VTDR were evaluated using generalized estimating equation models clustered by patient. Receiver operating characteristic (ROC) analysis assessed diagnostic performance. Results: Fifty-three eyes were graded as VTDR (54.6%) and 44 eyes as non-VTDR (45.4%). Median RIPL counts were 0 in non-VTDR and 4 in VTDR eyes. The ICC was 0.974 (95% confidence interval [CI], 0.949-0.986). Each additional RIPL increased the odds of having VTDR by 22% (95% CI, 1.09-1.37; P = 0.001). ROC analysis yielded an area under the curve of 0.813 (95% CI, 0.730-0.897), with an optimal threshold of 2.5 RIPLs having a sensitivity of 70% and specificity of 84% for detecting VTDR. Conclusions: RIPL count is a reproducible OCT biomarker for VTDR, validated against UWF-FA using low-density OCT scans. Translational Relevance: RIPLs offer a quantitative and practical OCT-based biomarker to identify diabetic patients at high risk for vision loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.